Overview of Brosol Compuesto

Brosol Compuesto is a fixed-dose combination (FDC) drug that provides a dual-action approach for managing certain respiratory conditions. It is clinically recognized and classified as a combined bronchodilator and mucolytic agent.

Quick Facts

Property	Description
Active Ingredients	Ambroxol hydrochloride, Clenbuterol hydrochloride
Form	Oral Solution, Syrup (Jarabe)
Pharmacological Class	Bronchodilator; Mucolytic Agent
Common Use	Easing breathing difficulty related to obstructed air flow and thick secretions
Origin	Synthetic

Identity and Classification

Brosol Compuesto is a synthetic medicine containing two active ingredients: Ambroxol hydrochloride and Clenbuterol hydrochloride. The World Health Organization (WHO) classifies the Ambroxol and Clenbuterol combination within the therapeutic group for drugs used in obstructive airway diseases. This classification confirms the medicine's role in addressing conditions affecting breathing capacity.

Its formulation, typically an Oral Solution or Syrup (Jarabe), facilitates the oral route of administration. The fixed-dose design ensures that both therapeutic components are delivered simultaneously to address complex respiratory symptoms effectively.

Core Composition and Purpose

The dual composition dictates the medicine's function. The Ambroxol component is recognized for its secretolytic action, meaning it helps reduce the viscosity and stickiness of bronchial secretions. Pharmacological studies confirm that Ambroxol assists the body in making thick mucus easier to clear.

Concurrently, the Clenbuterol component, a beta2-Sympathomimetic agent, acts to relax the muscle tissue that encircles the air passages, leading to their widening. This action is understood to help patients by easing the breathing difficulties associated with constricted airways. The overall purpose is to provide simultaneous relief for symptoms resulting from the difficult movement and retention of secretions and the involuntary narrowing of the air passages, such as during an acute exacerbation of a bronchopulmonary disease.

Regulatory References

World Health Organization (WHO) ATC/DDD Toolkit

What side effects are possible with Brosol Compuesto?

Possible side effects and safety information

Regulatory documents classify the potential side effects of Brosol Compuesto based on frequency and the body system affected. The overall safety profile is shaped by both active ingredients: the beta2-agonist Clenbuterol and the mucolytic Ambroxol.

Documented Adverse Reactions

The most frequently reported adverse reactions, generally classified as Common (ge1/100 to <1/10), are linked to the bronchodilator component. These include tremor, headache, and nervousness. Effects on the heart, such as tachycardia (rapid heart rate) and palpitations, are also classified within official safety documents.

Less frequent, Uncommon (ge1/1,000 to <1/100) reactions often involve the Gastrointestinal System, presenting as nausea, vomiting, diarrhea, or dry mouth. Reactions affecting the senses, such as dysgeusia (altered taste sensation), are also cited.

Serious Adverse Reactions and Safety Constraints

The official safety information includes the potential for rare, serious events. These Serious Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and severe Anaphylactic Reactions (including anaphylactic shock), are listed, though their frequency is often classified as Not Known.

Safety documents establish restrictions for use. The medicine is contraindicated in individuals with certain pre-existing conditions, including tachyarrhythmia and hyperthyroidism, due to the stimulating nature of the beta2-agonist component. Use is also restricted in patients with severe hepatic or renal dysfunction. Some effects, such as tremor and headache, are officially noted to be more frequent at the start of treatment or during dose escalation.

Overdose and Emergency Response

Brosol Compuesto Overdose and when to seek help

Overdose involving Brosol Compuesto requires immediate medical attention due to the documented toxicity profile, which is primarily driven by the Clenbuterol component. Ingestion of doses exceeding the usual amount may lead to manifestations consistent with beta2-adrenergic overstimulation.

Documented Clinical Manifestations

Overdose typically presents with tachycardia (rapid heart rate), palpitations, and involuntary muscle tremors. Other documented signs include central nervous system effects such as agitation and headache, alongside gastrointestinal effects like nausea and vomiting.

Severe Outcomes and Emergency Action

The regulatory profile classifies this overdose as potentially severe due to the risk of serious complications. Documented severe outcomes include myocardial ischemia and significant tachyarrhythmias. Physiologically, overdose may result in critical metabolic abnormalities, including hypokalemia (low blood potassium) and hyperglycemia.

If overdose is suspected, or if more than the recommended dose has been taken, immediate emergency help must be sought. Due to the long elimination half-life of Clenbuterol, hospitalization and continuous observation are required. Management is strictly symptomatic and supportive, and no specific antidote is known. Treatment procedures described in regulatory information include specific interventions like beta-blockade for cardiac effects and potassium repletion to manage electrolyte shifts.

Therapeutic Uses of Brosol Compuesto

The primary therapeutic role of Brosol Compuesto is to provide supportive relief for respiratory conditions where two major symptom challenges—airway obstruction and mucus retention—coincide. Its use is aligned with therapeutic strategies for acute and chronic processes presenting with both secretion retention and bronchospasm.

This medication is commonly used to help manage symptoms related to the tightening of the air passages, such as air flow obstruction and breathing difficulty, and the presence of viscous, difficult-to-clear bronchial secretions. It is relevant in conditions characterized by periods of heightened symptoms, such as bronchial asthma, COPD exacerbations, and acute bronchitis. The combined approach helps manage the symptom clusters of ineffective productive cough and respiratory strain.

“This approach is often relevant for providing supportive action against distressing physical symptoms in bronchopulmonary illnesses.”

By addressing the presence of both functional strain and the difficulty of mucus clearance, this medication supports patients who experience symptomatic discomfort, and may assist with comfort during acute episodes. The medication helps maintain a sense of stability when symptoms become more noticeable.

Quick Fact: Relief for Dual Symptoms
This combination is generally applied when the patient needs simultaneous support for tight breathing and thick phlegm retention.

Regulatory References

Cuban Center for State Control of Medicines (CECMED) Reference

Eligibility and Restrictions for Use

Brosol Compuesto is a combination medication containing ambroxol (a mucolytic) and clenbuterol (a bronchodilator). Its use is determined by a patient's underlying health conditions and current medications.

Who Can Use It

The medication is primarily indicated for patients suffering from acute and chronic respiratory diseases where both a retention of secretions and a narrowing of the airways (bronchospasm) are present. This includes conditions such as:

Acute and Chronic Bronchitis
Bronchial Asthma

Who Should Not Use It (Contraindications)

Brosol Compuesto is generally contraindicated in individuals with specific pre-existing heart conditions or hormonal imbalances due to the effects of clenbuterol. It should not be used by patients with:

Hyperthyroidism (overactive thyroid)
Subvalvular Aortic Stenosis
Tachyarrhythmias (rapid, irregular heart rhythm)

Caution is also advised, and dosage may need adjustment, for patients with decompensated diabetes or a recent myocardial infarction (heart attack). Simultaneous use with other sympathomimetic bronchodilators should only occur under strict medical supervision. The medication is typically not recommended during the first trimester of pregnancy or near delivery due to the uterine-inhibiting action of clenbuterol.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interactions for Brosol Compuesto (Ambroxol hydrochloride and Clenbuterol hydrochloride) as defined in government regulatory labeling. The product's dual composition results in specific restrictions across both its bronchodilator and mucolytic components.

Official Interaction Restrictions

Interaction Type	Interacting Agent	Official Regulatory Statement
Prohibited Combination	Beta-adrenergic blocking agents (beta-blockers)	Use is prohibited as these agents cause pharmacological antagonism that fully negates the intended bronchodilating action of Clenbuterol.
Not Recommended	Antitussives (Cough Suppressants)	Not recommended due to the risk of cough reflex depression by the antitussive, potentially leading to the retention and accumulation of secretions facilitated by Ambroxol.
Additive Pharmacodynamic Effect	Other beta2-Sympathomimetics, Methylxanthines, Corticosteroids, Diuretics	Co-administration may enhance systemic effects from the Clenbuterol component, increasing the risk of adverse cardiovascular reactions and hypokalemia.
Exposure Modification	Specific Antibiotics	The Ambroxol component is documented to increase the concentration of certain antibiotics (e.g., Amoxicillin, Erythromycin, Cefuroxime, Doxycycline) in lung tissues and bronchial secretions.

Population-Specific Interaction Note

Caution is warranted in patients with severe renal insufficiency as accumulation of Ambroxol metabolites is expected due to reduced renal elimination, which may alter the overall exposure profile of the drug.

Mechanism of Action

Regulation of Bronchial Muscle Tone

The bronchodilator component, Clenbuterol, works by acting as an agonist on beta2-Adrenergic Receptors (beta2-AR), which are linked to the cAMP second messenger system in the bronchial smooth muscle. Activation of this cascade causes the muscle tissue to relax, leading to an increase in the internal diameter of the air passages and a subsequent decrease in resistance to gas flow.

Liquefaction and Mobilization of Secretions

The mucolytic component, Ambroxol, engages mechanisms that reduce the viscoelasticity of bronchial secretions. It stimulates cells (Type II Pneumocytes) to increase the production of pulmonary surfactant and actively promotes the breakdown of the structural acid mucopolysaccharide fibers within the mucus. This results in the secretions becoming thinner and less adhesive, modifying the mucus-layer properties to support the natural rate of mucociliary transport.

Functional Synergy and Dual Action

The drug's overall profile stems from the functional complementarity of its two mechanisms. The combination's mechanisms target two distinct components: Clenbuterol modulates muscular tone (reduced spasm), while Ambroxol facilitates the mobilization of retained secretions. This coordinated intervention mechanistically modulates both the physiological processes governing airflow restriction and the viscoelastic properties of retained secretions simultaneously.

Dosage and Administration Information

Brosol Compuesto is administered via the oral route as a liquid solution or syrup. The usage pattern is defined by a structured, volume-based dosing schedule that requires precise measurement of the prescribed amount. To ensure accuracy, the oral solution must be measured using a calibrated device before each administration, a procedural step documented in the prescribing information.

The dosing regimen is structured around a biphasic frequency schedule. The general use frequency is two times per day (BID). However, in situations requiring more intensive initial support, the frequency may be temporarily increased to three times per day (TID). This higher-frequency regimen is restricted to the first 2 to 3 days of treatment only, after which the schedule must revert to the standard twice-daily frequency.

Adults and adolescents over 12 years are typically prescribed 20 mL per dose. The labeling includes detailed tiered dosing volumes for children, covering infants up to 8 months through children up to 12 years, underscoring the necessity of age-appropriate volume adherence.

Instructions also specify the protocol for managing missed doses. If a dose is missed, it should be taken as soon as possible, and the remaining administration schedule should be re-adjusted accordingly. The instructions state that taking a double volume to compensate for a missed dose is explicitly prohibited, maintaining the integrity of the labeled dosing schedule. The label does not contain specific instructions regarding administration relative to mealtimes.

Recent Clinical Evidence

Brosol Compuesto: Recent Clinical Evidence

Evidence for Use in Acute Respiratory Flare-ups

Research evaluated the application of Brosol Compuesto in conditions involving periods of heightened symptoms, specifically acute exacerbations of respiratory illnesses like bronchitis. Researchers conducted Randomized Controlled Trials (RCTs) and multicenter non-inferiority trials that focused on measuring outcomes related to physical discomfort. These studies examined short-term symptom change and patient-reported outcomes related to perceived discomfort. Studies report how symptoms evolved in the observed populations, with findings describing patterns observed regarding the speed of symptom change when compared against a control.

Research into Airway Clearance and Function

Beyond symptom scores, research has investigated the physiological effects relevant to breathing mechanisms. Controlled clinical trials that examined the physiological measures related to lung function monitored functional measures like tracheobronchial mucociliary clearance, which is the body's natural rate of clearing mucus. Data show patterns related to this clearance rate, and this evidence contributes to the broader evidence landscape by providing context on the combination's studied physiological effects in conditions like Chronic Obstructive Lung Disease (COLD).

Evidence in Special Populations

The research base includes dedicated studies that was evaluated in specific populations, most notably pediatric patients (children aged 2 to 14 years) with Acute Bronchitis. These findings describe group patterns, not personal outcomes. Conversely, for other groups, such as older adults or patients with multiple comorbidities, data for certain groups remain insufficient. While some adult patients was observed in controlled clinical trials examining functional outcomes, results apply only to the populations studied in those specific research settings.

What Remains Uncertain About the Research

A review of the evidence highlights several key limitations in the existing research. The core limitation is that the follow-up durations were limited across the primary efficacy trials, typically to 7 days. Consequently, it is not yet clear whether long-term effects are fully established. Furthermore, the strongest randomized data for the fixed-dose combination is concentrated in a relatively narrow pediatric population, meaning data remain insufficient for its broad use in all indicated adult groups.

Frequently Asked Questions (FAQ)

Common questions about Brosol Compuesto (FAQ)

Q: Is Brosol Compuesto the same as simple Brosol?

Brosol Compuesto is officially described as a fixed-dose combination (FDC) medicine. This means it contains two distinct active ingredients: Ambroxol hydrochloride and Clenbuterol hydrochloride. Its name reflects this dual composition, distinguishing it from single-ingredient formulations that may exist.

Q: Can Brosol Compuesto be taken if I am already taking an antibiotic?

Official documentation notes an interaction between the mucolytic component and certain antibiotics. It has been documented that the Ambroxol component may increase the concentration of antibiotics like Amoxicillin or Erythromycin in the lung tissues and bronchial secretions. This is a known interaction noted in official documents.

Q: Is it okay to take Brosol Compuesto at night?

The medicine contains a beta2-agonist component, which is a type of medicine known to affect the central nervous system. These effects can include nervousness and tremor. Taking the medicine too close to bedtime may be linked to these effects, and the timing of administration may need to be considered.

Q: Can taking Brosol Compuesto cause trouble sleeping?

Difficulty sleeping, or insomnia, is a documented side effect related to the active bronchodilator component. This ingredient is known to stimulate the central nervous system. Regulatory documents list nervousness and tremor as common adverse reactions, which can contribute to sleep disturbances.

Q: Are there any food or drinks that interact negatively with Brosol Compuesto?

Official instructions specify that there are no particular instructions regarding administration relative to general food or mealtimes. The regulatory label focuses on interactions with other medicines and products. Official regulatory labels primarily focus on drug-drug interactions.

Q: Why do some people feel dizzy after taking this medicine?

The active bronchodilator component is known to cause effects on the central nervous system. While common reactions include tremor and nervousness, dizziness is a frequently reported event associated with drugs in this pharmacological class.

Q: Can I take pain relievers like paracetamol with Brosol Compuesto?

Official regulatory documents do not list a specific interaction or restriction for co-administration with the single-ingredient pain reliever paracetamol (acetaminophen). The medicine has known additive effects with other sympathomimetics, which informs the overall caution for use with other medications. Official documents suggest that combinations with other medicines should be managed carefully.

Q: What are the possible interactions with alcohol described for Brosol Compuesto?

The medicine contains a component that acts on the central nervous system. Regulatory documents acknowledge the need for caution regarding the consumption of alcohol, given its central nervous system effects.

Q: Is Brosol Compuesto commonly prescribed for children?

Official regulatory documents confirm the medication is authorized for use in pediatric patients by defining detailed, tiered dosing volumes for children, from infants up to 12 years of age. This confirms its eligibility for use across various pediatric age groups.

Q: Does the evidence suggest Brosol Compuesto is effective for children's coughs?

Clinical research was evaluated in pediatric patients specifically with Acute Bronchitis. The studies focused on measuring outcomes related to short-term symptom change and patient-reported outcomes related to perceived discomfort in this group.

Q: How quickly should I expect Brosol Compuesto to start working?

Official documents on the drug's action state that the active bronchodilator component is quickly absorbed following oral administration. Peak concentrations of the medicine in the blood are typically achieved within 2 to 3 hours after taking a dose.

Q: Is Brosol Compuesto considered a stimulant?

The medicine contains Clenbuterol, which is classified as a beta2-Sympathomimetic agent. This pharmacological class is known to stimulate the heart and central nervous system. This stimulating action is the reason for potential side effects like nervousness and tremor.

Q: Is Brosol Compuesto available over-the-counter in some regions?

The regulatory status of the drug is determined by each country’s health authority. In many regions with explicit legal classifications, the product is designated as a prescription-only medicine.

Q: Does Brosol Compuesto affect the ability to drive or operate machinery?

Because the medicine is associated with central nervous system effects, such as tremor and nervousness, regulatory documents routinely include warnings about its potential impact on a person's ability to drive or operate machinery.

Q: Why is it important to check the ingredients of a 'compuesto' product like this?

As a fixed-dose combination (FDC) drug, it delivers two distinct active components with different mechanisms of action and safety profiles. Therefore, official documents confirm that the safety profile and potential drug-drug interactions for both active components are matters for careful review.

Q: Does Brosol Compuesto contain any ingredients that are restricted for athletes?

Official international regulatory bodies for sports have classified one of the active components, Clenbuterol, as a prohibited substance. Due to its classification, it is restricted for use by athletes in many competitive sporting activities.

Q: What should I do if I experience an allergic reaction to Brosol Compuesto?

The official safety information lists the potential for rare, serious events, including severe Anaphylactic Reactions. Official protocol requires urgent notification of a health professional for any severe or allergic reaction.

Q: Is Brosol Compuesto safe for breastfeeding mothers, according to official data?

Official data indicates that one of the active ingredients is present in breast milk. Due to a general lack of comprehensive data on the combined product and the known properties of the components, its use is often not recommended by manufacturers during breastfeeding.

Q: Are there any contraindications listed for people with glaucoma?

The list of official contraindications for the medicine is specific, covering conditions such as tachyarrhythmia and hyperthyroidism. Glaucoma is not explicitly listed in the official contraindications section provided in the regulatory text.

Q: Is it advisable to drink extra water while taking Brosol Compuesto?

The Ambroxol component of the medicine functions as a mucolytic agent, meaning it helps to liquefy secretions. Hydration is a physiological process that supports the body's natural function of clearing mucus.

Q: Are the side effects of Brosol Compuesto more common in certain age groups?

Official safety documents do not provide a general statement on side effect frequency based on age. However, some common effects like tremor and headache are officially noted to be more frequent at the start of treatment or during periods of dose escalation.

How should Brosol Compuesto be stored and disposed of?

How to Store and Dispose of Brosol Compuesto?

The official labeling for Brosol Compuesto Solution specifies mandatory conditions to maintain product stability and safety. The medicine must be stored at a temperature not exceeding 30 C and must be protected from light.

Storage Requirements

Storage Factor	Official Condition
Temperature	Do not exceed 30 C
Protection	Protect from light
Child Safety	Keep out of the reach of children
Stability	Do not use after the expiration date

Disposal Instructions

Official disposal rules require that unused or expired Brosol Compuesto be disposed of according to local regulations. Medications must not be thrown in household waste or discarded down the drain to comply with environmental protection guidelines. Consultation with a pharmacist can provide guidance on proper disposal procedures.

Brosol Compuesto